100%(6)6 out of 6 people found this document helpful
This preview shows page 1 - 2 out of 2 pages.
takes market share from Teva”. Therefore, the company’s growth has been attributed to the many acquisition of rivals and other players in the pharma market. However, the integration of all of those acquisition involve a lot of change management that could potentially slow down themain focus of the company.
Moreover, I think Teva will face a greater risk if it continues to invest a lot of its R&D in innovativeproducts. As mentioned in the articles below, Copaxone caused many problems. After, Copaxone lost patent exclusivity and it was exposed to generics competition, Teva lost almost 40% of its profits. The company was very dependent to its first innovative product and that’s why it was negatively affected by the generic competition.Also, I think that Teva could also be vulnerable to quality in order to keep the prices of drugs down. Generics are still perceived are of inferior quality in many parts of the world. Therefore, if Teva has issues with its quality it could damage penetration in other geographies. Resources:?module=ArrowsNav&contentCollection=Business%20Day&action=keypress®ion=FixedLeft&pgtype=article